Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GLSI
GREENWICH LIFESCIENCES, INC.
NASDAQ
$15.67
▼ DOWN 16.34% (-3.06)

KEY STATISTICS

Market Cap$230.01 M
52w High$34.10
52w Low$7.78
Dividend Yield—
Frequency—
P/E-11.96
Volume370.11K
Shares Out.14.68M

COMPANY

LEADERSHIP

Snehal S. Patel
CHIEF EXECUTIVE
Snehal S. Patel

COMPENSATION 2026

Salary$612,563
Stock Awards$5,322,841
Incentive Plan Pay$0
All Other Comp.$0
Total$6,241,685

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 25, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
13

PRICE TARGET

Target High$50.00
Target Low$50.00
Target Median$50.00
Target Consensus$50.00

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.—
NOV
13
FRI

PRICE

$15.67 ▼ DOWN 16.34% (−$3.06)
$15.00$16.50$18.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM15.67

About Greenwich LifeSciences, Inc.

https://greenwichlifesciences.com ↗

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company developing novel HER2/neu-targeted cancer immunotherapies, with its lead candidate GP2 having completed Phase IIb trials to prevent breast cancer recurrence.

INDUSTRY

Biotechnology

A PRODUCT GREENWICH LIFESCIENCES, INC. IS KNOWN FOR

GLSI-100 (GP2 + GM-CSF)
GLSI-100 (GP2 + GM-CSF)

GLSI-100 is a Phase III cancer immunotherapy combining GP2 and GM-CSF to prevent breast cancer recurrence in HER2-positive patients, with FDA Fast Track status.

COMPETITORS

COMPETITOR
ANIX COMPARE
BCTX COMPARE
PBYI COMPARE
PGEN COMPARE
SLS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
49
LISTED HERE
10
RANKED BY POSITION SIZE
VTS.AX
0.00% · 199.0K
XSU.TO
0.00% · 178.3K
R2SC.L
0.01% · 18.6K
GSSC
0.02% · 9.1K
FSML
0.07% · 5.3K
XRS2.DE
0.00% · 4.9K
RSSL
0.00% · 3.2K
RFLR
0.02% · 1.1K
OMFS
0.01% · 765
URTY
0.00% · 274

INSTITUTIONAL OWNERSHIP

SHARES OWNED
11.88%
HOLDERS
77
TOP 12 OF 77 · RANKED BY POSITION SIZE
Blackrock, Inc.
433.9K sh · $10.42M
Blackrock Inc.
308.9K sh · $5.33M
Vanguard Group Inc
296.6K sh · $6.23M
Geode Capital Management, LLC
155.5K sh · $3.74M
State Street Corp
133.9K sh · $3.22M
Nuveen, LLC
88.7K sh · $2.13M
Credit Agricole S A
87.0K sh · $1.83M
Northern Trust Corp
75.9K sh · $755.25K
Bank Of New York Mellon Corp
46.5K sh · $1.12M
Russell Investments Group, Ltd.
39.7K sh · $953.55K
Goldman Sachs Group Inc
39.5K sh · $949.29K
Renaissance Technologies LLC
38.4K sh · $382.08K

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CEO AND CFO
Patel Snehal
Purchase · 1.5K shares
2026-07-28
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CEO AND CFO
Patel Snehal
Purchase · 700 shares
2026-07-29
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CEO AND CFO
Patel Snehal
Purchase · 1.5K shares
2026-07-27
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CEO AND CFO
Patel Snehal
Purchase · 1.1K shares
2026-07-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
IMMX$13.94COMPARE
AGEN$7.66COMPARE
IRD$3.69COMPARE
SRZN$22.42COMPARE
HURA$2.11COMPARE
SEER$1.98COMPARE
CGTX$1.02COMPARE
ONCY$0.86COMPARE